Discontinued — last reported Q3 '24
Business Segments · Restructuring, impairment, and related charges, net
U.S. Pharmaceutical — Restructuring, impairment, and related charges, net
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ3 2024
Last reportedQ3 2024
How to read this metric
An increase suggests significant operational changes, potential business unit consolidation, or asset value deterioration, while a decrease indicates operational stability and fewer non-recurring charges.
Detailed definition
This metric represents the net impact of costs associated with organizational restructuring, asset impairments, and rela...
Peer comparison
Similar to 'Restructuring and impairment charges' reported by other large-scale pharmaceutical wholesalers and logistics providers.
Metric ID:
mck_segment_u_s_pharmaceutical_restructuring_impairment_and_related_charges_netHistorical Data
1 periods
| Q3 '24 | |
|---|---|
| Value | $63.00M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — restructuring, impairment, and related charges, net?
- McKesson (MCK) reported u.s. pharmaceutical — restructuring, impairment, and related charges, net of $63.00M in Q3 2024.
- What does u.s. pharmaceutical — restructuring, impairment, and related charges, net mean?
- The net cost incurred from reorganizing business operations or writing down the value of assets within the U.S. Pharmaceutical segment.